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Immunogenicity and reactogenicity of combined 
versus separately administered DTPw-HBV and Hib 
vaccines given to healthy infants at 2,4 and 6 months 
of age, with a booster at 18 months 
Stella Riedemann,(‘) German Reinhardt,(‘) Jaime Jara, Richard Rios,(‘) 
Maria Soledad Wenzel,(l) Paul Willems, and Hans L. Bockc2) 
Objectives: To determine the immunogenicity and reactogenicity of a combined DTPw-HBV/Hib vaccine, in com- 
parison with DTPw-HBV and Hib vaccines given as separate concomitant injections. 
Methods: In an open, randomized study, healthy infants were injected with either DTPw-HBV/Hib vaccine or 
separate DTPw-HBV and Hib vaccines at 2,4 and 6 months of age, with a booster at 18 months. 
Results: Both vaccination regimens were immunogenic, with seropositivity rates of 100% after the booster vaccination 
for all vaccine components. Even as early as 2 months after the second dose of the primary vaccination, most patients 
had seroprotective antibody titers, the proportion of seropositive subjects approaching 100% for tetanus, hepatitis 
B, and Hib. Post-primary and post-booster geometric mean titers (GMTs) were well above seroprotective thresholds 
for each vaccine antigen in both groups, with no clinically relevant differences in the groups. The separate and 
combined administrations showed comparable reactogenicity profiles, and neither showed a significant increase in 
reactogenicity with successive doses. 
Conclusions: The results of this study support the combination of Hib and DTPw-HBV vaccination in routine infant 
immunization at 2,4 and 6 months of age with a booster at 18 months. Maximum benefit is obtained from compliance 
with the full course, but substantial benefit is likely to be achieved even in partially compliant patients, provided they 
receive at least two doses. Furthermore, these results demonstrate the tolerability of a fourth (booster) administration, 
where the addition of the Hib vaccine to DTPw-HBV did not lead to an increase in the overall reactogenicity. 
Int J Infect Dis 2002; 6: 215-222 
INTRODUCTION 
Vaccination during childhood provides an effective 
and cost-effective method of protecting against many 
diseases. Consequently, programs for mass vaccination 
of children are widespread in both developed and 
developing countries. However, with the increasing 
number of diseases for which effective vaccines can be 
given, vaccination programs have the potential to 
involve a large numbers of injections. 
A common strategy to reduce the number of 
injections is the use of combination vaccines, in which 
a single injection contains more than one vaccine.1,2 
Combination vaccines in widespread use include diph- 
theria, tetanus and pertussis (DTP) vaccine, and measles, 
mumps and rubella (MMR) vaccine. There are many 
advantages to combining vaccines in this way: not only 
does it reduce discomfort for patients by sparing them 
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multiple injections, but it also reduces costs. Reduced 
costs come from many factors, such as fewer clinic visits, 
fewer syringes and needles, and a reduced requirement 
for cold storage of vaccines.3 Moreover, when vaccina- 
tions are given separately, there is greater scope for 
missed doses,4 so combination vaccines can also increase 
compliance, and hence the overall effectiveness of 
vaccination programs. However, before combination 
vaccines can be routinely incorporated into vaccination 
programs, it is essential to demonstrate that the com- 
bination is well tolerated and does not adversely affect 
the immunogenicity of any of the vaccine components. 
The World Health Organization (WHO), through 
its expanded Programme on Immunization (EPI), has 
recently recommended that Haemophilus influenzae 
type b (Hib) vaccine should be included in routine 
infant immunization programs.5 H. influenzae type b 
(Hib) is responsible for a substantial burden of disease 
in developed and developing countries, with about 3 
million cases of serious disease and 400 000-700 000 
deaths annually in young children.5 It can cause various 
diseases, including meningitis and pneumonia.6 Menin- 
gitis caused by Hib can have severe neurologic sequelae, 
even when promptly treated with appropriate anti- 
biotics,’ so it is highly desirable that children should be 
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protected against Hib infection by vaccination. Vaccina- 
tion programs can be effective in preventing Hib in- 
fection: the incidence of invasive H. influenzae infection 
in children aged less than 5 years fell by 97% during the 
period 1987-97 in the USA, where routine immuniza- 
tion with Hib conjugate vaccines was introduced in 
1988.8 There is also evidence that Hib vaccination can 
be effective in preventing invasive disease in developing 
countries.‘,iO 
The strategy of combination with DTP vaccine 
has already been adopted for including hepatitis B 
vaccination (HBV) into immunization prograes. The 
WHO has recommended that all children should be 
vaccinated against hepatitis B, and stresses the benefits 
of combined DTPw-HBV vaccination.” Tritanrix-HB 
is a combined DTPw-HBV vaccine manufactured by 
GlaxoSmithKline Biologicals, in accordance with that 
recommendation, and its immunogenicity and favorable 
reactogenicity profile have been well established.12-l6 
This study was done to investigate the immunogenicity 
and reactogenicity of Hib vaccination when given in 
combination with a DTPw-HBV vaccine, in comparison 
with separate administration. 
MATERIALS AND METHODS 
Ethics 
The study was approved by the Ethics Review Com- 
mittee of the Valdivia Hospital before any patients were 
enrolled, and was conducted in accordance with the 
Declaration of Helsinki (Hong Kong revision, 1989) and 
the Good Clinical Practice guidelines in force at the time. 
The parents or guardians of all subjects gave written 
informed consent to participate. 
Study population, trial design, and vaccines 
Subjects included in the study were healthy male and 
female infants, aged 6-12 weeks at the time of the first 
vaccination. Exclusion criteria were presence or history 
of significant disease, history of allergic disease, immuno- 
suppressive therapy, and any previous vaccination other 
than with oral polio vaccine or BCG vaccine. Subjects 
were excluded from further participation in the study if 
they experienced severe systemic adverse reactions to 
vaccination. 
The study was a randomized controlled trial with an 
open comparative parallel-group design. Vaccinations 
were given at approximately 2,4 and 6 months of age. 
The interval between vaccinations ranged from 5 to 
11 weeks. A booster vaccination was given at approxi- 
mately 18 months of age. 
Subjects were randomly allocated to one of two 
groups, in a ratio of 1 : 1. Subjects in group 1 received 
a combined diphtheria, tetanus, whole-cell pertussis, 
hepatitis B and H. influenzae type b (DTPw-HB/Hib) 
vaccine, prepared extemporaneously by reconstituting a 
lyophilized Hib-tetanus conjugate vaccine (Hiberix, 
GlaxoSmithKline Biologicals) with a liquid DTPw- 
HBV vaccine (Tritanrix-HB, GlaxoSmithKline Bio- 
logicals). The vaccine was given by intramuscular 
injection in the right arm. Subjects in group 2 received 
the same vaccines, but given in two separate intra- 
muscular injections: Hib in the left deltoid, and 
DTPw-HBV in the right deltoid. For the booster dose 
at 18 months of age, all subjects received the combined 
vaccine. 
Data collection 
Parents took subjects to health care centers, or the study 
nurse visited the subject’s home. The study nurses then 
used diary cards to record local and systemic signs and 
symptoms for the day of each vaccination and the 3 
following days (a total of 4 days per vaccination). Nurses 
were asked to rate the severity of pain at the injection 
site, and the size of any redness or swelling. They were 
also asked to record the child’s rectal temperature and 
rate the severity of the following systemic symptoms: 
irritability, unusual crying, drowsiness, feeding problems, 
diarrhea, and vomiting. After establishment by the 
investigator of their relationship with vaccination in 
terms of related, possibly related or unrelated, systemic 
symptoms were classified, together with pain at the 
injection site, as mild (easily tolerated), moderate 
(sufficiently discomforting to interfere with the infant’s 
daily activities), or severe (prevents normal daily 
activities). In addition, they recorded any other adverse 
experiences occurring during the first 4 days after 
vaccination on the diary cards. At each subsequent visit, 
the investigator transcribed information from the diary 
cards onto the Case Report Form, and asked about any 
other adverse experiences that occurred after the period 
covered by the diary card. 
Serology 
Venous blood samples were collected for immunologic 
assays immediately before the first vaccination, 610 
weeks after the second dose, 3-6 weeks after the third 
dose, and immediately before and 3-6 weeks after the 
booster dose. The serum collected from those samples 
was stored at -20°C until it was analyzed, with a 
blinding procedure, at GlaxoSmithKline Biologicals in 
Rixensart, Belgium. 
Antidiphtheria and antitetanus antibodies were 
determined by enzyme-linked immunosorbent assay 
(ELISA), with a cutoff of 0.1 IU/mL. Although anti- 
diphtheria and antitetanus titers >O.Ol IU/mL are 
generally considered to be protective, and the ELISA 
results are well correlated with in vivo neutralization 
tests,17Js this correlation may be reduced at antibody 
titers ~0.1 IU/mL. Therefore, a titer of 0.1 IU/mL by 
ELISA was conservatively set as the cutoff. Anti- 
Bordetella pertussis antibodies were determined using a 
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whole-cell based commercial ELISA kit with an assay 
cutoff of 1.5 EL.U/mL (Labsystem, ICNFLOW, Helsinki, 
Finland). Anti-HBs antibody titers were measured using 
a commercial radioimmunoassay kit (AUSAB, Abbott 
Laboratories, North Chicago, IL, USA), with a cutoff 
of 10 mIU/mL. A radiolabeled antigen-binding assay 
(RABA) was used to measure the antibodies against the 
Hib polysaccharide, PRP, with a cutoff of 0.15 ug/mL. All 
cutoff values were considered to be seroprotective titers, 
with the exception of B. pertussis, for which a sero- 
protective level is not established. In this case, a vaccine 
response was measured and defined as a postvaccination 
antibody titer above the cutoff of 15 EL.U/mL in initially 
seronegative subjects, and a post-primary vaccination 
antibody titer equal to or greater than the initial titer 
(post-booster titer 12 times greater) in initially sero- 
positive subjects. 
Statistical methods 
To test the baseline comparability of the two groups, the 
ratios of males to females were compared using Fisher’s 
exact test, and age was compared between groups by 
two-way ANOVA with the factors group, sex, and 
group x sex interaction. The null hypothesis that the two 
treatments were equally reactogenic was tested by 
comparing the proportions of subjects with specific 
symptoms between groups using Fisher’s exact test. The 
null hypothesis that the two treatments were equally 
immunogenic was tested in two ways. The proportions of 
patients with seroprotective titers after vaccination 
were compared between groups using Fisher’s exact 
test. For pertussis, there is no serologic correlate of 
protection, so the statistical test for this component 
instead compared the proportions of patients fulfilling 
the criterion for a vaccine response. A vaccine response 
was defined as a postvaccination antibody titer above 
the cutoff of 1.5 EL.U/mL in initially seronegative 
subjects, and a postvaccination antibody titer equal to or 
greater than the initial titer in initially seropositive 
subjects, For the booster dose, vaccine response to 
pertussis was defined as an antibody titer above the 
assay cutoff in subjects who were seronegative before 
the booster, and a post-booster titer r2 times the pre- 
booster titer in initially seropositive subjects.The second 
statistical test of immunogenicity was a comparison of 
the postvaccination antibody titers using Student’s t-test 
with log-transformed data. Antibody titers are presented 
as geometric means, with confidence intervals calculated 
from the log-transformed data. 
RESULTS 
Patients studied 
In total, 120 infants entered the study, 52 females and 68 
males. The mean age was 9.9 (range S-12) weeks. Each 
treatment group comprised 60 subjects, and there were 
no significant differences in sex ratio or age between 
the groups. Only one subject was excluded from the 
reactogenicity analysis, for having received a vaccine 
other than the study vaccine. The analysis of immuno- 
genicity for the initial series of three vaccinations in- 
cluded 101 subjects (84% of those entering the study); 
the most common reason for exclusion from the analysis 
was failure to comply with the vaccination schedule. 
Ninety-one subjects received all three vaccinations 
according to the protocol. 
Seventy subjects (36 from group 1 and 34 from 
group 2) received the booster injection at 18 months. Of 
those subjects, 62 (89 / ) ‘0 were included in the immuno- 
genicity analysis, the remainder being excluded for failure 
to comply with the blood-sampling schedule. 
Immunogenicity 
Vaccination in both groups was clearly immunogenic for 
all five vaccine components. Even as early as 2 months 
after the second vaccination, most patients had sero- 
protective antibody titers, the proportion of seropositive 
subjects approaching 100% for tetanus, hepatitis B, 
and Hib (Table 1). Seropositivity rates increased after 
Table 1. Percentages of patients with seroprotective antibody titers (or with titers above the assay cutoff for pertussis) 
Group Pre-dose Post-dose II Post-dose Iii Pre-booster Post-booster 
N 1 47 46b 41 32 32 
2 54” 54c 40 30 30 
Diphtheria 1 12.8% 84.8% 97.6% 68.8% 100.0% 
2 14.8% 73.6% 97.5% 70.0% 100.0% 
Tetanus 1 4.3% 97.8% 100.0% 96.9% 100.0% 
2 9.3% 98.1% 100.0% 90.0% 100.0% 
Pertussis 1 6.4% 69.6% 97.6% 65.6% 100.0% 
2 5.6% 81.5% 100.0% 76.7% 100.0% 
HB 1 4.3% 95.7% 97.6% 90.6% 100.0% 
2 0.0% 94.4% 100.0% 96.7% 100.0% 
Hib 1 31.9% 97.8% 100.0% 100.0% 100.0% 
2 38.5% 98.1% 100.0% 96.7% 100.0% 
V/=52 for Hib; bN=47 for HB; CN=53 for diphtheria. 
None of the differences between groups 1 and 2 is statistically significant. 
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subsequent vaccinations, and after the booster vaccina- 
tion all subjects had seroprotective antibody titers for 
diphtheria, tetanus, hepatitis B, and Hib. The vaccine 
response rates to the whole-cell B. pertussis component 
were 97.6% in group 1 and 100% in group 2 after the 
third dose, and 100% in group 1 and 96.7% in group 
2 after the booster. The percentages of subjects with 
seropositive antibody titers were very similar in the 
two groups, and the differences in those percentages 
between the groups were not significant for any of the 
components after any vaccination. 
Reactogenicity 
There were no more reactions reported in the combined 
administration group (53.4% of doses) than in the 
separate group (62.2% of doses). As can be seen from 
Tables 2 and 3, showing the incidences of systemic and 
local reactions, differences between groups 1 and 2 were 
Table 2. Overall incidence of all and severe solicited local 
reactions after primary vaccination course (three vaccine 
doses administered at 2, 4 and 6 months respectively) 
Group I (N=162) Group 2 (N=172) 
Right limb Right limb Left limb 
(DTP-HBV-Hib) (DTP-HBVj (Hib) 
Pain 
All 17.9% 13.4% 12.8% 
Severe 1.2% 1.2% 1.2% 
Redness 
All 12.3% 4 1%” 6.4% 
>20 mm 1.2% o:o% 0.6% 
Swelling 
All 9.9% 7.0% 6.4% 
>20 mm 1.9% 0.0% 0.0% 
asignificantly different from group 1, P=O.OOS. 
Severe pain was defined as preventing normal daily activities. 
Table 3. Incidence of all and severe solicited systemic 
reactions (% of all vaccinations) 
Primary vaccination course Booster 
Group 1 Group 2 Group 1 Group 2 
(N=762) (N=172) (N=35) (N =33) 
Diarrhea 1.9 1.2 0.0 0.0 
Severe 0.0 0.0 0.0 0.0 
Drowsiness 14.8 15.7 2.9 9.1 
Severe 0.0 0.0 0.0 0.0 
Feeding problems 6.8 8.7 2.9 3.0 
Severe 0.0 0.0 0.0 0.0 
Irritability 30.2 36.6 17.1 27.3 
Severe 0.6 0.6 0.0 0.0 
Fever t 38°C 32.1 39.5 28.6 36.4 
Fever 2 39.5X 0.6 1.2 2.9 0.0 
Vomiting 2.5 2.3 0.0 0.0 
Severe 0.0 0.0 0.0 0.0 
primary vaccination course included administration of three vaccine 
doses at 2, 4 and 6 months of age, respectively. 
not statistically significant, except for redness, which was 
significantly more common in group 1 than at the site of 
the DTP-HBV injection in group 2 (P=O.OOS, Fisher’s 
exact test). However, in spite of the absence of clinically 
significant differences between the two groups, the 
separate administration of DTPw-HB and Hib causes 
local reactions after each injection, in this case 17.4% 
added to 16.3%, compared to 22.7% in the case of the 
DTPw-HB/Hib combination. It is noteworthy that the 
incidence of severe pain at the injection site was low, and 
no cases of severe pain lasted for more than 24 h. Local 
reactions after the booster vaccination were similar 
(data not shown). 
The incidence of systemic reactions decreased with 
successive doses of primary vaccination and after the 
booster dose. For each individual dose, there was a trend 
towards an increased incidence of systemic symptoms in 
group 2 (Figure l), although this did not reach statistical 
significance. The most common solicited symptoms 
were fever, irritability, and drowsiness (Table 3). Most 
solicited symptoms were considered ‘related’ or ‘possibly 
related’ to treatment by the investigator. The majority 
of symptoms lasted for less than 24 h, and few were 
classified as severe. 
In addition to the solicited signs and symptoms, 184 
doses during the primary vaccination phase and 26 doses 
during the booster phase were followed by at least one 
unsolicited adverse event. They were all considered by 
the investigator to be unrelated to treatment and they 
were equally distributed between the two groups. The 
events were mostly of the kind that are common in 
children of that age: the most frequent ones included 
bronchitis (42), pharyngitis (22), respiratory disorders 
(30), viral infections (23), anemia (14), and conjunctivitis 
(13). Other unsolicited events were either rare (less than 
five cases) or isolated. Among the unsolicited adverse 
events listed above, six were serious adverse events 
(SAEs), three in each group, reported during the primary 
vaccination phase of the study. They included five cases 
of bronchopneumonia accompanied by related mani- 
festations, and one case of apnea due to gastroeso- 
phageal reflux. All were considered to be unrelated to 
the study vaccination, and all patients recovered without 
sequelae. 
DISCUSSION 
The results of this study show clearly that the com- 
bination of Hib vaccine with DTPw-HBV does not 
compromise the immunogenicity of any of the com- 
ponents. For all five components of the combined 
vaccine, seroconversion rates and antibody geometric 
mean titers (GMTs) after each vaccination were similar 
whether Hib vaccine was given in combination with or 
separately from the other components. 
Both administrations proved to be highly immuno- 
genic, and even after only two vaccinations the sero- 
conversion rates were very high.This could be important 
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Dose 1 Dose 2 Dose 3 Booster 
Figure 1. Total incidence of symptoms after each vaccination. 
in developing countries, where compliance with the full 
course of injections might not be as high as in a clinical 
trial setting. Nonetheless, the results of this study do not 
support a reduction in the recommended number of 
injections, as seroconversion rates were still higher after 
the third dose. 
Serologic measurements immediately before the 
booster showed that the antibody titers had persisted 
over a l-year period. Although titers were lower at this 
time than at 1 month after the third dose, they were still 
substantially higher than before the primary vaccination, 
and were still at seroprotective levels in most subjects. 
The dramatic increases in antibody titers after the 
booster are typical of an anamnestic response, showing 
that the immune system was effectively primed by the 
earlier course of injections. There was no clear differ- 
ence between the two groups in the response to the 
booster, which shows that the priming of the immune 
system is not compromised by combining the Hib vaccine 
with the other components. 
The GMTs of antibodies confirmed the similar 
immunogenicity of the two modes of vaccine admini- 
stration (Figures 2-6). The only statistically significant 
difference between the treatment groups was higher 
T T 
anti-PRP titers after the booster vaccination in group 1 
(P=O.O07), but that difference is unlikely to be clinically 
significant, as the GMT in each group was substantially 
above the seroprotective level, and all subjects had 
protective antibody titers.19,20 
Concern has been raised that the immune response 
to Hib vaccines might be compromised when given in 
combination with DTP vaccines.21,22 However, the 
results of this study show clearly that this is not true of 
the vaccines used in this study, which has also been 
shown in earlier studies.23,24 However, this phenomenon 
appears to be confined to DTPa;25,26 it may be possible 
that the adjuvant effect of the Pw component com- 
pensates for any suppression of the Hib response.27 
The addition of the Hib vaccine to the DTPw-HB 
combination did not lead to an increase in the overall 
reactogenicity. There was a trend towards a higher 
incidence of local reactions for the combination vaccine, 
which was significant for redness. However, it must be 
borne in mind that giving the Hib vaccine separately 
requires twice as many injections as the combination 
vaccine, so the overall burden of local reactions may 
be lower for the combined vaccine. In any case, local 
tolerability was good for both regimens, with a low 
Pre- Post-dose 2 Post-dose 3 Pre-booster Post-booster 
vaccination 
Figure 2. Geometric mean titers (-c95% confidence intervals) of antidiphtheria antibodies. 
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Figure 4. Geometric mean titers (295% confidence intervals) of anti-B. pertussis antibodies. 
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Figure 5. Geometric mean titers (*95% confidence intervals). 
incidence of severe injection site reactions. Moreover, were classified as severe, showing the good tolerability 
the incidence of local reactions was less than the rates of both treatments. This is the first report of admini- 
reported by Gustafsson et a128 for DTPw vaccine alone; stration of a fourth (booster) dose. Neither the com- 
in particular, pain was reported in more than 50% of bined nor separate administration of these vaccines 
doses compared to 17.9% in our study. Systemic reactions caused any significant increase in reactogenicity; in fact, 
to the vaccine were also similar in both treatment groups. the converse was observed when vaccine was given as a 
Most systemic reactions resolved within 24 h, and few booster in the second year of life. 
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vaccination booster 
**P < 0.01 Group 1 versus Group 2. t-test 
Figure 6. Geometric mean titers (+95% confidence intervals) of anti-PRP antibodies. 
The results of this study are consistent with those of 
other studies in which Hib vaccine has been given in 
combination with DTP-HBV vaccines. Win et al also 
found that the combined vaccine had similar immuno- 
genicity and reactogenicity to separate vaccinations, 
with doses given at 1.5,3 and 5 months of age.23 Bravo 
et al compared combined and separate vaccinations 
with Hib and DTPw-HBV at the WHO recommended 
schedule of 6,10 and 14 weeks of age, after a dose of 
HBV given at birth. 24 Again, there was little difference 
between the two regimens in either immunogenicity or 
reactogenicity. Usonis et al also found the combination 
of Hib with DTPw-HBV to be highly immunogenic with 
vaccinations at 3,4.5 and 6 months of age.*” 
In conclusion, the results of this study add to 
evidence from other studies that the Hib and DTPw- 
HBV vaccines used in this study can be combined in the 
same syringe without compromising immunogenicity or 
tolerability. However, the results of this study cannot be 
generalized to combinations other than that of Hiberix 
with Tritanrix-HB, which are both, including the com- 
bination, WHO approved. Combinations of Hib and 
DTPw-HBV vaccines from other manufacturers would 
require separate studies to demonstrate their immuno- 
genicity and tolerability. 
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